||Apoptotic Signaling Pathway and Resistance to Apoptosis in Breast Cancer Stem Cells -- Anti-Cancer Strategy of Transitional Cell Carcinoma of Bladder Based on Induction of Different Types of Programmed Cell Deaths -- Apoptosis in Carcinogenesis and Chemoherapy of the Uterine Cervix -- Apoptosis in Colorectal Tumorigenesis and Chemotherapy -- Apoptosis in Cutaneous Melanoma -- Apoptosis in Carcinogenesis and Chemotherapy - Esophageal Cancer -- Molecular Targets in Gastric Cancer and Apoptosis -- Apoptosis and the Tumor Microenvironment in Hematologic Malignancies -- Bcl-2 Family Members in Hepatocellular Carcinoma (HCC) - Mechanisms and Therapeutic Potentials -- Apoptosis in the Development and Treatment of Laryngeal Cancer: Role of p53, Bcl-2 and Clusterin -- Cyclooxygenase 2 and its Metabolites: Implications for Lung Cancer Therapy -- Roles of Negative and Positive Growth Regulators in Nasopharyngeal Carcinoma -- Cellular Signaling Mechanisms in Pancreatic Apoptosis -- Strategies to Circumvent Resistance to Apoptosis in Prostate Cancer Cells by Targeted Necrosis -- Carcinogenesis and Therapeutic Strategies for Thyroid Cancer. The purpose of this book is to provide information on apoptotic processes involved in major neoplastic diseases and their translations into emerging anti-cancer strategies. The book is divided into 15 chapters, each of which will be focused on one particular cancer (breast, bladder, cervical, colorectal, esophageal, gastric, laryngeal, liver, lung, nasopharyngeal, pancreatic, prostate, thyroid, leukaemia and cutaneous malignant melanoma). A number of established leaders in the field have critically summarized the recent discoveries concerning apoptosis in a particular cancer and its potential for anti-cancer treatment. The book describes how the apoptosis plays a role in the specific carcinogen-induced cellular and molecular changes during the development of the cancer, and critically discusses how the emerging anti-cancer strategy can be built by the utilization of the specific carcinogen-related apoptotic pathway. Therefore, this book will be not only for laboratory-based molecular and cell biologists and biochemists in cancer research but also for clinical oncologists and those working in the pharmaceutical and biotechnological industries.